Strategizing the clone wars: Pharmacological control of cellular sensitivity to radiation

Molecular Interventions

Volumn 10, Issue 6, 2010, Pages 341-353

  Kimple, Randall J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MERCAPTOPURINE; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PEMETREXED; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB; VORINOSTAT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL HYPOXIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DNA ALKYLATION; DRUG HALF LIFE; DRUG MECHANISM; GASTROINTESTINAL TUMOR; GENE ACTIVATION; GLIOMA; HEAD AND NECK CANCER; HISTONE MODIFICATION; HUMAN; IONIZING RADIATION; METASTASIS; NONHUMAN; RADIOSENSITIZATION; REVIEW; SOLID TUMOR; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; COMBINED MODALITY THERAPY; DNA REPAIR; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 79551468957     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.10.6.3     Document Type: Review

References (114)

1. Pignon JP, Bourhis J, Domenge C, and Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955.
2. Anonymous (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348:1049-1054.
3. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A, et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530.
4. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, and Insalaco S (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144-1153. (Pubitemid 29177873)
5. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466.
6. Heidelberger C, Griesbach L, Cruz O, Schnitzer RJ, and Grunberg E (1958) Fluorinated pyrimidines. VI. Effects of 5-fluorouridine and 5-fluoro-2′- deoxyuridine on transplanted tumors. Proc Soc Exp Biol Med 97:470-475.
7. Moertel CG, Reitemeier RJ, Childs DS, Jr., Colby MY, and Holbrook MA (1964) Combined 5-fluorouracil and supervoltage radiation therapy in the palliative management of advanced gastrointestinal cancer: a pilot study. Mayo Clin Proc 39:767-771. This landmark study was one of the first clinical reports describing the use of concurrent chemotherapy and radiation.
8. Nigro ND, Vaitkevicius VK, and Considine B, Jr. (1974) Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 17:354-356. This "preliminary" trial presaged the current standard of care for anal cancer by investigating the use of 5-FU and mitomycin C given concurrently with radiation. Initiated as a pre-op regimen, the unexpectedly high rate of complete patient responses led the Wayne State team to eliminate radical surgery from the initial management of anal cancer.
9. Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, and Johnson DH (2000) A randomized trial of postoperative adjuvantpy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 343:1217-1222.
10. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578. This is the first randomized trial to demonstrate a survival benefit for a therapeutic antibody given concurrently with radiation.
11. Kvols LK (2005) Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets. J Nucl Med 46 Suppl 1:187S-190S.
12. Verheij M, Vens C, and van Triest B (2010) Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist Updat 13:29-43.
13. Tofilon PJ and Camphausen K (2009) Molecular targets for tumor radiosensit thera ization. Chem Rev 109:2974-2988.
14. Spalding AC and Lawrence TS (2006) New and emerging radiosensitizers and radioprotectors. Cancer Invest 24:444-456.
15. Hall EJ and Giaccia AJ (2006) Radiobiology for the radiologist, 6th ed, Lippincott Williams and Wilkins, Philadelphia. Required reading for anyone studying radiation biology, radiation therapy, or utilizing ionizing radiation for research.
16. Tallarida RJ (2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298:865-872.
17. Steel GG and Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5:85-91.
18. Eastman A (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34: 155-166.
19. Richmond RC (1984) Toxic variability and radiation sensitization by dichlorodiammineplatinum(II) complexes in Salmonella typhimurium cells. Radiat Res 99:596-608. (Pubitemid 14031874)
20. Amorino GP, Freeman ML, Carbone DP, Lebwohl DE, and Choy H (1999) Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys 44:399-405.
21. Yang LX, Douple EB, and Wang HJ (1995) Irradiation enhances cellular uptake of carboplatin. Int J Radiat Oncol Biol Phys 33:641-646.
22. Joschko MA, Webster LK, Bishop JF, Groves J, Yuen K, Olver IN, Narayan KN, and Ball DL (1997) Radioenhancement by cisplatin with accelerated fractionated radiotherapy in a human tumour xenograft. Cancer Chemother Pharmacol 40:534-539.
23. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, and Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865.
24. Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, and Creaven PJ (1995) Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 97:177-184.
25. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, and Chaney SG (1994) Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54:3500-3505.
26. Bischof M, Weber KJ, Blatter J, Wannenmacher M, and Latz D (2002) Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys 52:1381-1388.
27. Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, and Weber KJ (1998) Radiosensitizing potential of gemcitabine (2′,2′-difluoro- 2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 41:875-882. (Pubitemid 28285968)
28. Longley DB, Harkin DP, and Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338.
29. Lawrence TS, Tepper JE, and Blackstock AW (1997) Fluoropyrimidine- Radiation Interactions in Cells and Tumors. Semin Radiat Oncol 7:260-266.
30. Berger SH, Pittman DL, and Wyatt MD (2008) Uracil in DNA: consequences for carcinogenesis and chemotherapy. Biochem Pharmacol 76:697-706.
31. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730.
32. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, and Rich TA (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507.
33. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, et al. (2008) Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299:1019-1026.
34. Shewach DS and Lawrence TS (1995) Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol 22:68-71.
35. Lawrence TS, Chang EY, Hahn TM, and Shewach DS (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res 3:777-782.
36. Wachters FM, van Putten JW, Maring JG, Zdzienicka MZ, Groen HJ, and Kampinga HH (2003) Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 57:553-562.
37. Robinson BW, Im MM, Ljungman M, Praz F, and Shewach DS (2003) Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res 63:6935-6941. (Pubitemid 37322979)
38. Shewach DS, Hahn TM, Chang E, Hertel LW, and Lawrence TS (1994) Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218-3223. (Pubitemid 24208931)
39. Zhao J, Kim JE, Reed E, and Li QQ (2005) Molecular mechanism of antitumor activity of taxanes in lung cancer (Review). Int J Oncol 27:247-256.
40. Tishler RB, Schiff PB, Geard CR, and Hall EJ (1992) Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613-617. This study established the radiosensitizing properties of taxol and linked the drug's action to effects on the cell cycle.
41. Chen Y, Pandya K, Keng PP, Feins R, Raubertas R, Smudzin T, Rosenblatt J, and Okunieff P (2001) Schedule-dependent pulsed paclitaxel radiosensitization for thoracic malignancy. Am J Clin Oncol 24:432-437. (Pubitemid 32959097)
42. Gupta N, Hu LJ, and Deen DF (1997) Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int J Radiat Oncol Biol Phys 37:885-895. (Pubitemid 27181323)
43. Ingram ML and Redpath JL (1997) Subadditive interaction of radiation and Taxol in vitro. Int J Radiat Oncol Biol Phys 37:1139-1144.
44. Herscher LL, Hahn SM, Kroog G, Pass H, Temeck B, Goldspiel B, Cook J, Mitchell JB, and Liebmann J (1998) Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol 16:635-641. (Pubitemid 28135610)
45. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, and Peters LJ (1995) Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55:3564-3568.
46. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, et al. (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378.
47. Mason K, Staab A, Hunter N, McBride W, Petersen S, Terry N, and Milas L (2001) Enhancement of tumor radioresponse by docetaxel: Involvement of immune system. Int J Oncol 18:599-606.
48. Cao W, Shiverick K, Namiki K, Sakai Y, Porvasnik S, Urbanek C, and Rosser C (2008) Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World Journal of Urology 26: 509-516.
49. Amorino GP, Hamilton VM, and Choy H (1999) Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro. Radiat Oncol Investig 7:343-352.
50. Hennequin C, Giocanti N, and Favaudon V (1995) S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 71:1194-1198.
51. Chen AY, Okunieff P, Pommier Y, and Mitchell JB (1997) Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 57:1529-1536.
52. Kim JS, Amorino GP, Pyo H, Cao Q, and Choy H (2002) Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS- 2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiother Oncol 62:61-67.
53. Larsen AK, Escargueil AE, and Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99:167-181.
54. Escargueil AE, Plisov SY, Skladanowski A, Borgne A, Meijer L, Gorbsky GJ, and Larsen AK (2001) Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling. FASEB J 15:2288-2290.
55. Janss AJ, Cnaan A, Zhao H, Shpilsky A, Levow C, Sutton L, and Phillips PC (1998) Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents etoposide in human brain tumor cell lines. Anticancer Drugs 9:641-652.
56. Kaufmann SH (1991) Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129-1136.
57. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, and Slack JA (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045-9051.
58. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, and Jiricny J (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54:334-341.
59. Jansen M, Bardenheuer W, Sorg UR, Seeber S, Flasshove M, and Moritz T (2001) Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones. Eur J Haematol 67:2-13. (Pubitemid 32769809)
60. Wedge SR, Porteous JK, Glaser MG, Marcus K, and Newlands ES (1997) In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8:92-97.
61. Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, and Camphausen K (2008) In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 14:931-938.
62. Brown JM and Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447.
63. Brown JM, Mehta MP, and Nieder C (2006) Multimodal concepts for integration of cytotoxic drugs, Springer, New York.
64. Denny WA and Wilson WR (2000) Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin Investig Drugs 9:2889-2901.
65. Thoms J and Bristow RG (2010) DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol 20:217-222.
66. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, and Schmidt-Ullrich R (1999) Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10:2493-2506. This report described radiation-induced activation of the epidermal growth factor receptor and downstream signaling pathways and provided rationale for investigating inhibitors of EGFR signal transduction pathways as radiosensitizers.
67. Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K, and Schmidt-Ullrich RK (2002) Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21:4032-4041. (Pubitemid 34679244)
68. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S, and Schmidt-Ullrich R (2003) Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 159:283-300.
69. Chinnaiyan P, Allen GW, and Harari PM (2006) Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol 16:59-64.
70. Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM, and Sartor CI (2010) Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res 16:912-923.
71. Sambade MJ, Kimple RJ, Camp JT, Peters E, Livasy CA, Sartor CI, and Shields JM (2010) Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts. Int J Radiat Oncol Biol Phys 77:575-581.
72. Sambade MJ, Camp JT, Kimple RJ, Sartor CI, and Shields JM (2009) Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol 93:639-644.
73. Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z, and Kolesnick RN (1994) Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 180:525-535. This paper demonstrated the potential role of radiation in altering cellular membrane composition and subsequently initiating apoptosis and established the crucial role of non-DNA-mediated effects in the radiation response.
74. Huang SM, Bock JM, and Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940.
75. Huang SM and Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166-2174.
76. Harari PM, Allen GW, and Bonner JA (2007) Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25:4057-4065.
77. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, and Slamon DJ (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355. (Pubitemid 29136268)
78. Horton JK, Halle J, Ferraro M, Carey L, Moore DT, Ollila D, and Sartor CI (2010) Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys 76:998-1004.
79. Harrington KJ, El-Hariry IA, Holford CS, Lusinchi A, Nutting CM, Rosine D, Tanay M, Deutsch E, Matthews J, D'Ambrosio C, et al. (2009) Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 27:1100-1107.
80. Kimple RJ, Sartor CI, Chiu WM, Esler L, Livasy CA, Carey LA, Halle J, and Dees EC (2010) Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer. Int J Radiat Oncol Biol Phys 78:S210. In the phase I trial reported here, we utilized serial biopsies to assess biomarkers of response to dual EGFR/Her2 inhibition.
81. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, and Bernhard EJ (2003) The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 22:5866-5875.
82. Brunner TB, Gupta AK, Shi Y, Hahn SM, Muschel RJ, McKenna WG, and Bernhard EJ (2003) Farnesyltransferase inhibitors as radiation sensitizers. Int J Radiat Biol 79:569-576.
83. Appelmann I, Liersch R, Kessler T, Mesters RM, and Berdel WE (2010) Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy. Recent Results Cancer Res 180:51-81.
84. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62.
85. Witte L, Fuks Z, Haimovitz-Friedman A, Vlodavsky I, Goodman DS, and Eldor A (1989) Effects of irradiation on the release of growth factors from cultured bovine, porcine, and human endothelial cells. Cancer Res 49:5066-5072.
86. Nieder C, Wiedenmann N, Andratschke NH, Astner ST, and Molls M (2007) Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience. Rev Recent Clin Trials 2:163-168.
87. Kruser TJ, Wheeler DL, Armstrong EA, Iida M, Kozak KR, van der Kogel AJ, Bussink J, Coxon A, Polverino A, and Harari PM (2010) Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin Cancer Res 16:3639-3647.
88. Koukourakis MI, Giatromanolaki A, Sheldon H, Buffa FM, Kouklakis G, Ragoussis I, Sivridis E, and Harris AL (2009) Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab. Clin Cancer Res 15:7069-7076.
89. Verbrugge I, de Vries E, Tait SW, Wissink EH, Walczak H, Verheij M, and Borst J (2008) Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene 27:574-584.
90. Wissink EH, Verbrugge I, Vink SR, Schader MB, Schaefer U, Walczak H, Borst J, and Verheij M (2006) TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother Oncol 80:214-222.
91. Marini P, Schmid A, Jendrossek V, Faltin H, Daniel PT, Budach W, and Belka C (2005) Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 5:5.
92. Marini P, Budach W, Niyazi M, Junginger D, Stickl S, Jendrossek V, and Belka C (2009) Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions. Int J Radiat Oncol Biol Phys 75:198-202.
93. Verbrugge I, Wissink EH, Rooswinkel RW, Jongsma J, Beltraminelli N, Dupuis M, Borst J, and Verheij M (2009) Combining radiotherapy with APO010 in cancer treatment. Clin Cancer Res 15:2031-2038.
94. Xu L, Yang D, Wang S, Tang W, Liu M, Davis M, Chen J, Rae JM, Lawrence T, and Lippman ME (2005) (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 4:197-205.
95. Zerp SF, Stoter R, Kuipers G, Yang D, Lippman ME, van Blitterswijk WJ, Bartelink H, Rooswinkel R, Lafleur V, and Verheij M (2009) AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat Oncol 4:47.
96. Dai Y, Liu M, Tang W, DeSano J, Burstein E, Davis M, Pienta K, Lawrence T, and Xu L (2008) Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin Cancer Res 14:7701-7710.
97. Thraves P, Mossman KL, Brennan T, and Dritschilo A (1985) Radiosensitization of human fibroblasts by 3-aminobenzamide: an inhibitor of poly(ADP-ribosylation). Radiat Res 104:119-127.
98. Kelland LR, Burgess L, and Steel GG (1988) Differential radiosensitization by the poly(ADP-ribose) transferase inhibitor 3-aminobenzamide in human tumor cells of varying radiosensitivity. Int J Radiat Oncol Biol Phys 14:1239-1246.
99. Brock WA, Milas L, Bergh S, Lo R, Szabo C, and Mason KA (2004) Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 205:155-160.
100. Noel G, Godon C, Fernet M, Giocanti N, Megnin-Chanet F, and Favaudon V (2006) Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther 5:564-574.
101. Cerna D, Camphausen K, and Tofilon PJ (2006) Histone deacetylation as a target for radiosensitization. Curr Top Dev Biol 73:173-204.
102. Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, and Tofilon PJ (2004) Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 64:316-321.
103. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, and Tofilon PJ (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114:380-386. An intriguing report from a group at the National Cancer Institute that demonstrates the radiosensitizing ability of an agent approved for non-cancer use.
104. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, and Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163.
105. Kim GD, Choi YH, Dimtchev A, Jeong SJ, Dritschilo A, and Jung M (1999) Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J Biol Chem 274:31127-31130.
106. Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, Frascogna V, Varna M, Opolon P, Castedo M, Bourhis J, et al. (2009) The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle 8:3172-3181.
107. Dai Y and Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16:376-383.
108. Tao Y, Leteur C, Yang C, Zhang P, Castedo M, Pierre A, Golsteyn RM, Bourhis J, Kroemer G, and Deutsch E (2009) Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 8:1196-1205.
109. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, et al. (2010) Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 70:4972-4981.
110. Sidi S, Sanda T, Kennedy RD, Hagen AT, Jette CA, Hoffmans R, Pascual J, Imamura S, Kishi S, Amatruda JF, et al. (2008) Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133:864-877.
111. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J, and Jackson SP (2006) ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 8:37-45.
112. Rogers PB, Plowman PN, Harris SJ, and Arlett CF (2000) Four radiation hypersensitivity cases and their implications for clinical radiotherapy. Radiother Oncol 57:143-154.
113. Avondoglio D, Scott T, Kil WJ, Sproull M, Tofilon PJ, and Camphausen K (2009) High throughput evaluation of gamma-H2AX. Radiat Oncol 4:31. Compared with standard drug development, the use of high-throughput assays for identification of radiosensitizers has lagged far behind. This paper described a method for performing high-throughput evaluation of DNA-damage as a potential screen for radiosensitizers.
114. Tepper JE and Sartor CI (2006) Radiation therapy and biologics: a ripe opportunity? Nat Clin Pract Oncol 3:463.